Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.

卡培他滨 医学 阿法替尼 埃罗替尼 内科学 结直肠癌 克拉斯 肿瘤科 耐火材料(行星科学) 癌症 表皮生长因子受体 生物 天体生物学
作者
Amy Chang,Safi Shahda,William Proctor Harris,Stacey A. Cohen,Andrew L. Coveler,Bert H. O’Neil,Vijayakrishna K. Gadi,Reina Hibbert,Hannah H. Lee,Anne Younger,Kinsey A. McCormick,Colin C. Pritchard,Mary W. Redman,E. Gabriela Chiorean
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (4_suppl): TPS515-TPS515 被引量:2
标识
DOI:10.1200/jco.2017.35.4_suppl.tps515
摘要

TPS515 Background: The epidermal growth factor receptor (EGFR)/HER2 pathway is overactive in several solid tumors, including gastroesophageal, hepatic, colorectal, and pancreatico-biliary cancers. Afatinib is an irreversible inhibitor of the Erb family approved for metastatic non-small cell lung cancer with EGFR mutations. Afatinib downregulates thymidine synthase (TS) the intracellular target of fluoropyrimidine chemotherapy such as capecitabine. Treatment of colorectal cancer cell lines with cytotoxic drugs can up-regulate EGFR expression, and increase sensitivity to EGFR inhibition. Based on this preclinical rationale, and given that capecitabine is commonly used in refractory gastrointestinal cancers, we have developed a phase I/Ib trial to evaluate the safety and maximum tolerated dose (MTD) of afatinib with capecitabine in advanced solid tumors, and assess preliminary antitumor activity in pts with refractory pancreatico-biliary cancers at MTD. Methods: Eligible pts have metastatic solid tumors (phase I) or pancreatico-biliary cancers (phase Ib), ECOG PS 0-2 (PS 0-1 phase Ib), any number of prior therapies (phase I), or ≤ 2 prior therapies (phase Ib), no prior erlotinib (phase Ib), and have archived paraffin embedded tumor tissue, or ability to undergo tumor biopsy at baseline. Tumor tissue is analyzed with UW-OncoPlex, a multiplexed gene sequencing panel of 200+ cancer-related genes, to identify predictive biomarkers of benefit. The study design is standard “3+3”. Afatinib is administered orally (PO) daily (QD) in escalating doses of 20, 30 and 40 mg, with capecitabine at 1000 mg/m 2 PO BID Days 1-14, in 21-day cycles (C). Dose limiting toxicity (DLT) is assessed in C1. Once the MTD is identified, the phase Ib expansion cohorts will enroll 15 pts each with refractory pancreatic and biliary cancers, with afatinib dosed at MTD and standard dose capecitabine. The study was activated in November 2015, and to date 4 pts were enrolled in cohort 1, 3 pts in cohort 2, and 2 pts in cohort 3. The phase I is ongoing and the phase Ib is expected to start enrollment in December 2016. Clinical trial information: NCT02451553.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
路宝发布了新的文献求助10
刚刚
lius发布了新的文献求助10
刚刚
1秒前
lxt发布了新的文献求助10
1秒前
深情安青的应助被开朗的慕儿采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
duyi0521完成签到,获得积分10
2秒前
2秒前
霁月发布了新的文献求助10
2秒前
drizzle发布了新的文献求助10
2秒前
Sonder完成签到,获得积分10
2秒前
2秒前
2秒前
fangkong发布了新的文献求助10
2秒前
zaq66996发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
3秒前
hsn发布了新的文献求助10
3秒前
Sandy完成签到,获得积分10
3秒前
kkkklo发布了新的文献求助10
3秒前
岁岁平安完成签到,获得积分10
3秒前
李健的小迷弟的应助被mengxiang采纳,获得10
4秒前
kinji完成签到,获得积分10
4秒前
霁月发布了新的文献求助10
5秒前
Lucas的应助被XY采纳,获得10
5秒前
霁月发布了新的文献求助10
5秒前
Lucas的应助被二马三乡采纳,获得10
5秒前
李爱国的应助被甜蜜的曼寒采纳,获得10
5秒前
5秒前
朴实夏寒发布了新的文献求助10
6秒前
manman发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182602
求助须知:如何正确求助?哪些是违规求助? 9572033
关于积分的说明 21821767
捐赠科研通 7779061
什么是DOI,文献DOI怎么找? 3433684
关于科研通互助平台的介绍 2557863
邀请新用户注册赠送积分活动 2479732